A Clinical Scoring System Predicting the Osteosarcoma Chemotherapy Drug Resistance

Ling ZHOU; Feng-di HU; Rong LI; Ye-dan LIAO; Zheng-qin GENG; Jia-dai TANG; Xue-qi ZHANG; Lin XIE; Zuo-zhang YANG

doi:10.12259/j.issn.2095-610X.S20210144

Volume 42 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(1): 29-37

Ling ZHOU, Feng-di HU, Rong LI, Ye-dan LIAO, Zheng-qin GENG, Jia-dai TANG, Xue-qi ZHANG, Lin XIE, Zuo-zhang YANG. A Clinical Scoring System Predicting the Osteosarcoma Chemotherapy Drug Resistance[J]. Journal of Kunming Medical University, 2021, 42(1): 29-37. doi: 10.12259/j.issn.2095-610X.S20210144

Citation:

Ling ZHOU, Feng-di HU, Rong LI, Ye-dan LIAO, Zheng-qin GENG, Jia-dai TANG, Xue-qi ZHANG, Lin XIE, Zuo-zhang YANG. A Clinical Scoring System Predicting the Osteosarcoma Chemotherapy Drug Resistance[J]. Journal of Kunming Medical University, 2021, 42(1): 29-37. doi: 10.12259/j.issn.2095-610X.S20210144

Citation:

Ling ZHOU, Feng-di HU, Rong LI, Ye-dan LIAO, Zheng-qin GENG, Jia-dai TANG, Xue-qi ZHANG, Lin XIE, Zuo-zhang YANG. A Clinical Scoring System Predicting the Osteosarcoma Chemotherapy Drug Resistance[J]. Journal of Kunming Medical University, 2021, 42(1): 29-37. doi: 10.12259/j.issn.2095-610X.S20210144

PDF( 837 KB)

A Clinical Scoring System Predicting the Osteosarcoma Chemotherapy Drug Resistance

doi: 10.12259/j.issn.2095-610X.S20210144

1.
Dept.of Gastrointestinal Oncology，The Third Affiliated Hospital of Kunming Medical University/Tumor Hospital of Yunnan Province，Kunming Yunnan 650118
2.
Dept.of Respiratory and Critical Care Medicine，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan Hubei 430030
3.
Bone and Soft Tissue Tumors Research Center of Yunnan Province，Dept. of Orthopaedics，The Third Affiliated Hospital of Kunming Medical University/Tumor Hospital of Yunnan Province，Kunming Yunnan 650118，China

Received Date: 2020-11-06
Available Online: 2021-01-26
Publish Date: 2021-01-26

Abstract

Abstract

Objective The purpose of this study was to develop a scoring system to predict chemotherapy resistance of osteosarcoma, which could guide doctors to better choose the appropriate treatment. Methods 119 cases of osteosarcoma with neoadjuvant chemotherapy were diagnosed by pathology at the Third Affiliated Hospital of Kunming Medical University between January 2013 and December 2017 and the covariates including general situation, blood indexes, initial diagnosis, treatment mode, therapeutic effect and survival were analyzed. Results According to RECIST 1.1, 78 of 119 patients were evaluated as stable disease（SD group）and 41 as progressive disease（PD group）; There was signifcant difference in staging, initial visit time, initial tumor size, neoadjuvant chemotherapy cycle, types of chemotherapy drugs, lymphocyte/leukocyte prechemotherapy, neutrophils/lymphocytes prechemotherapy, albumin prechemotherapy, ALP prechemotherapy, Uric acid prechemotherapy, BUN after the chemotherapy, uric acid after the chemotherapy, LDL prechemotherapy, TGF-β score, TCNR between SD group and PD group（P < 0.05）. Metastasis had no significant effect on the efficacy of chemotherapy. According to the ROC curve, the best cut-off value showed staging≥III, neoadjuvant chemotherapy cycle≤3, Lymphocyte/leukocyte prechemotherapy≤0.32, neutrophils/lymphocytes ≤1.98, albumin prechemotherapy, ≥48 g/L, BUN after the chemotherapy≥4.22 mmol/L, uric acid after the chemotherapy≥305 umol/L. TGF-β score≥8.5 was the risk factor for chemotherapy resistance in patients with osteosarcoma.3. Patients with one risk factors add 1, and 0-3 were classified as group 1. 4-6 were listed as group 2; 7-9 were listed as group 3 and there was no statistically significant difference between the three groups. Conclusion This study explored the clinical factors related to chemotherapy resistance of osteosarcoma.
- Osteosarcoma,
- Chemotherapy,
- Drug resistance,
- Scoring system

FullText(HTML)

References(20)

References

[1]	MirabelloL,Troisi R J,Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004:Data from the surveillance,epidemiology,and end results program[J]. Cancer,2009,115(7):1531-1543. doi: 10.1002/cncr.24121
[2]	Singh R,Shirali R,Chatterjee S,et al. Epidemiology of cancers among adolescents and young adults from a tertiary cancer center in Delhi[J]. Indian Journal of Medical & Paediatric Oncology Official Journal of Indian Society of Medical & Paediatric Oncology,2016,37(2):90-94.
[3]	Allison D C,Carney S C,Ahlmann E R,et al. A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era[J]. Sarcoma,2012,1(10):704872.
[4]	Luetke A,Meyers P A,Lewis I,et al. Osteosarcoma treatment-Where do we stand? A state of the art review[J]. Cancer Treatment Reviews,2014,40(4):523-532. doi: 10.1016/j.ctrv.2013.11.006
[5]	A Biazzo,M De Paolis. Multidisciplinary approach to osteosarcoma.[J]. Acta Orthop Belg,2016,82(4):690-698.
[6]	Kansara,Maya,Teng,et al. Translational biology of osteosarcoma[J]. Nature Reviews Cancer,2014,14(11):722-735. doi: 10.1038/nrc3838
[7]	Hogendoorn P C W,Athanasou N,Bielack S,et al. Bone sarcomas:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2010,21(5):21-26.
[8]	Guenther L M,Rowe R G,Acharya P T,et al. Response Evaluation Criteria in Solid Tumors(RECIST)following neoadjuvant chemotherapy in osteosarcoma[J]. Pediatric Blood & Cancer,2018,65(4):e26896.
[9]	Kim M S,Lee S Y,Cho W H,et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients[J]. Journal of Surgical Oncology,2008,97(5):456-461. doi: 10.1002/jso.20986
[10]	Lettieri C K,Appel N,Labban N,et al. Progress and opportunities for immune therapeutics in osteosarcoma[J]. Immunotherapy,2016,8(10):1233-1244. doi: 10.2217/imt-2016-0048
[11]	Yugui sun,lifeiZhang. The clinical use of pretreatment nlR,PlR,and lMR in patients with esophageal squamous cell carcinoma:evidence from a meta-analysis[J]. Cancer Management and Research,2018,10(22):6167-6179.
[12]	Munn,Lance L. Cancer and inflammation[J]. Wiley Interdisciplinary Reviews:Systems Biology and Medicine,2017,9(2):e1370. doi: 10.1002/wsbm.1370
[13]	Guthrie G J K,Charles K A,Roxburgh C S D,et al. The systemic inflammation-based neutrophil–lymphocyte ratio:Experience in patients with cancer[J]. Critical Reviews in Oncology/Hematology,2013,88(1):218-230. doi: 10.1016/j.critrevonc.2013.03.010
[14]	Abe S,Kawai K,Nozawa H,et al. LMR predicts outcome in patients after preoperative chemoradiotherapy for stage II-III rectal cancer[J]. Journal of Surgical Research,2018,222(2):122-131.
[15]	Hsu,Jun-Te,Wang,Chia-Cheng,Le,Puo-Hsien. Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes[J]. Journal of Surgical Research,2016,202(2):284-290.
[16]	M Whirl-Carrillo,E M McDonagh,J M Hebert. Pharmacogenomics Knowledge for Personalized Medicine[J]. Clinical Pharmacology & Therapeutics,2012,92(4):414-417.
[17]	Zhou J,Wen Q,Li S F,et al. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma[J]. Oncotarget,2016,7(31):50612-50623. doi: 10.18632/oncotarget.9437
[18]	Nanayakkara A K,Follit C A,Chen G,et al. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells[J]. Scientific Reports,2018,8(1):967. doi: 10.1038/s41598-018-19325-x
[19]	LvY,Ding X S,Li Y,et al. High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients[J]. Cancer Biomarkers,2016,16(1):89-97. doi: 10.3233/CBM-150544
[20]	Holmes K E,Thompson V,Piskun C M,et al. Canine osteosarcoma cell lines from patients with differing serum alkaline phosphatase concentration display no behavioural differences in vitro[J]. Veterinary & Comparative Oncology,2015,13(3):166-175.

Relative Articles(20)

Relative Articles

[1]	Binbin MA, Shaoxiong ZHANG, Yongli GAO. Bioinformatics-based Investigation of the Prognostic Value of ESCRT-related Genes in Osteosarcoma Assessment. Journal of Kunming Medical University, 2025, 46(4): 1-10.
[2]	Chunyan LIU, Bingqing CHANG, Chao LI, Xin REN, Xiaoqin LIU. Correlations between CD4⁺CD25⁺Treg，sCD30 and Clinical Characteristics of Lymphoma and Their Value in Predicting Infection after Chemotherapy. Journal of Kunming Medical University, 2024, 45(4): 1-6.
[3]	Jiang WU, Jiang ZHANG, Yanyan FEI, Qin LIU, Yuanjiao CHEN, Yuanxiao WANG, Shuifen DAI. Application of Knowledge-attitude-behavior Continuation in Nursing Education for Nasopharyngeal Cancer Patients After Radiotherapy and Chemotherapy. Journal of Kunming Medical University, 2024, 45(10): 166-172. doi: 10.12259/j.issn.2095-610X.S20241026
[4]	Jianming SUN, Yuan LI, Qin SU. The Clinical Features and Antibiotic Selection in Children with Acute Leukemia Complicated by Bloodstream Infections from Multidrug-Resistant Bacteria. Journal of Kunming Medical University, 2024, 45(11): 1-7.
[5]	Jiang WU, Shuifen DAI, Qin LIU, Shoutao YANG, Jiang ZHANG, Jiao YANG, Qiongyao GUAN. Effect of Nutrition Clinical Nursing Pathway for Nasopharyngeal Carcinoma Patients Concurrent Radiotherapy and Chemotherapy. Journal of Kunming Medical University, 2023, 44(5): 185-190. doi: 10.12259/j.issn.2095-610X.S20230510
[6]	Xiaomei JIN, Jieyan HE, Jichang SHI, Hui XING, Hong WANG, Ju ZHANG, Lijuan DONG, Lihua HUANG, Min CHEN, Zhijuan CHEN, Huichao CHEN. Virus Genotypes and Drug Resistance among HIV/AIDS Patients before Antiretroviral Therapy in Dali Bai Autonomous Prefecture in 2018. Journal of Kunming Medical University, 2023, 44(11): 152-157. doi: 10.12259/j.issn.2095-610X.S20231123
[7]	Shuangshuang WANG, Yaling LI, Liqin CHEN, Yonghui HAN, Mingbiao MA, Xiaojuan LI. The Analysis of Risk Factors and Drug Resistance of CRE Infection in Children’s Intensive Care Unit. Journal of Kunming Medical University, 2023, 44(9): 49-54. doi: 10.12259/j.issn.2095-610X.S20230918
[8]	Tingting YU, Hongying WANG, Runwu ZHANG, Jing BAI, Dong PU, Dongling LI. Analysis of Drug Resistance Mutation-related Sites in 1 452 Chronic Hepatitis B Patients with Low Viral Load in Kunming Area. Journal of Kunming Medical University, 2022, 43(9): 43-47. doi: 10.12259/j.issn.2095-610X.S20220927
[9]	Tingting YU, Dongling LI, Hongying WANG, Lihua LI, Dong PU, Kunli WU. Investigations on the Infection, Immunity and Drug Resistance of Newly-treated Cases of HIV in Kunming. Journal of Kunming Medical University, 2022, 43(1): 138-143. doi: 10.12259/j.issn.2095-610X.S20220133
[10]	Lianyong CHEN, Haohao RU, Xing YANG, Shuangqun YAN, Tao CHEN, Qinxuan NI, Lin XU. Characteristics of katG and inhA Gene Mutations in INH-Resistant Mycobacterium Tuberculosis in Yunnan Province. Journal of Kunming Medical University, 2022, 43(8): 28-33. doi: 10.12259/j.issn.2095-610X.S20220803
[11]	Jinyi GU, Deyao DENG, Wenli YUAN, Qiuping YANG, Jianmei SONG, Yanjun SHEN, Yuanyuan GUO, Hongyun XU. Clinical Distribution and Drug Resistance Analysis of Acineto Bacterbaumannii from 2014 to 2020. Journal of Kunming Medical University, 2022, 43(5): 83-87. doi: 10.12259/j.issn.2095-610X.S20220504
[12]	Peizheng XIANG, Mengli LI, Yan FU. Value of Multiple Scoring Systems in Evaluating the Prognosis of Liver Cirrhosis Complicated with Esophageal and Gastric Varices Bleeding. Journal of Kunming Medical University, 2022, 43(3): 128-134. doi: 10.12259/j.issn.2095-610X.S20220316
[13]	Wen-jing SUN, Man-ting HU, Na LI, Fei GE, Wen-lin CHEN, Yang LIU. Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer. Journal of Kunming Medical University, 2021, 42(7): 143-149. doi: 10.12259/j.issn.2095-610X.S20210724
[14]	Xiao-qin LI, Min ZHOU, Lin WANG, Hai-yan ZENG, Peng-ju LUO, Li-jia LIN. Efficacy of PCR-reverse Dot Hybridization in Drug Resistance Gene Detection and Drug Sensitivity of BD960 Tuberculosis in Drug Resistance Tuberculosis Detection. Journal of Kunming Medical University, 2020, 41(12): 138-141. doi: 10.12259/j.issn.2095-610X.S20201238
[15]	Li Shan Shan , Quan Yu Hang , Gong Ling Li , Yang Hui , Pu Jing Hong , Wang Zhong Hui . . Journal of Kunming Medical University, 2020, 41(05): 103-107.
[16]	Zhang Jin Yu , Peng Zhuo Hui . Relationship between Single Nucleotide Polymorphisms of ERCC Gene and Survival of Osteosarcoma. Journal of Kunming Medical University, 2017, 38(09): 59-65.
[17]	Lu Bin . . Journal of Kunming Medical University,
[18]	Wang Ruo Tian . . Journal of Kunming Medical University,
[19]	Li Chong Yang . . Journal of Kunming Medical University,
[20]	Dai Wei . . Journal of Kunming Medical University,